This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Molecular mechanisms of proteinopathies across neurodegenerative disease: a review
Neurological Research and Practice Open Access 16 September 2019
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Wischik, C. M. et al. O3-04-07: Tau aggregation inhibitor (TAI) therapy with Rember™ arrests disease progression in mild and moderate Alzheimer's disease over 50 weeks. Alzheimers Dement. 4, T167 (2008).
Mullard,A. Sting of Alzheimer's failures offset by upcoming prevention trials. Nature Rev. Drug Discov. 11, 657–660 (2012).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Related links
Rights and permissions
About this article
Cite this article
Gerald, Z., Ockert, W. Alzheimer's disease market: hope deferred. Nat Rev Drug Discov 12, 19–20 (2013). https://doi.org/10.1038/nrd3922
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd3922
This article is cited by
-
Molecular mechanisms of proteinopathies across neurodegenerative disease: a review
Neurological Research and Practice (2019)
-
The role of amyloidogenic protein oligomerization in neurodegenerative disease
Journal of Molecular Medicine (2013)